# QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

> **NCT03169764** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **ImmunityBio, Inc.**

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Avelumab
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Capecitabine
- **BIOLOGICAL:** Cetuximab
- **DRUG:** Cisplatin
- **DRUG:** cyclophosphamide
- **DRUG:** 5-Fluorouracil (5-FU)
- **DRUG:** fulvestrant
- **DRUG:** leucovorin
- **DRUG:** nab-paclitaxel
- **BIOLOGICAL:** nivolumab
- **DRUG:** Lovaza
- **RADIATION:** Stereotactic Body Radiation Therapy
- **BIOLOGICAL:** ALT-803
- **BIOLOGICAL:** ETBX-011
- **BIOLOGICAL:** ETBX-021
- **BIOLOGICAL:** ETBX-051
- **BIOLOGICAL:** ETBX-061
- **BIOLOGICAL:** GI-4000
- **BIOLOGICAL:** GI-6207

## Key facts

- **NCT ID:** NCT03169764
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-12
- **Primary completion:** 2019-01
- **Final completion:** 2021-12-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial not initiated
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03169764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03169764, "QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03169764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*